The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Personally I do think this is clutching at straws... id love to be corrected.
What we need for starters is the BOD to actually provide and engage with the shareholders like they state numerous times in presentations but never seem to deliver.
This isnt a "deal" this is more of a collaboration/ study
Question…..Where does the Val scientific advisory board fit into all of this?
The Company must post a notice convening a general meeting within 21 days from the date on which the requisition notice was received, and this general meeting must be held on a date not more than 28 days after the date of the notice to shareholders convening the general meeting.
The time line from requisition to termination was 4th March - 30th April 2020 therefore for Suzy to leave could follow the same time line… therefore might not drag on forever.
They also mentioned there would be a business update in March and company investors presentation.
As you stated the company did state “watch this space” between now and there therefore logic would state there must be some solid news in the next 4 to 6 weeks
I agree with AIMGambler tbf….
Needs something to get it out of the 1’s something that is high 2’s or it will be in the 1-2 region for a while imo
Like it or not Porky is factually correct in what he says in terms of possibilities….process and timelines.
Val did it with there last CEO George Morris in favour of Suzy…..
In regards to PYC - Dr Sargent needs time and the reasons VAL or questioning the BOD as there has been historical promises never delivered and the share prices has been decimate.
DoseMe, a leading provider of precision dosing software for therapeutic drug monitoring (TDM) and creators of DoseMeRx and DoseMe Analytics, today announced the appointment of Siegfried Braeuer to Director, International Sales. In this role, he will lead the expansion of DoseMe’s Model Informed Precision Dosing (MIPD) platform through channel partners and direct sales across multiple continents.
Siegfried Braeuer brings a wealth of experience in pharma with a long tenure at Merck. Additional roles at Swiss Alpinopharma, Amarin GmbH, Interim Management/Consulting and Canpharma, added to Siegfried ‘Sigi’ vast experience building teams across the emerging markets of the Eastern Europe, Middle East, and Africa region. Braeuer, an alumnus of Johannes Kepler University Linz and the MBA program at Emory University, joins DoseMe with more than 20 years of experience leading high-performance teams across pharmaceutical, commercialization and technology spanning multiple geographies including US, UK, Brazil and India.
“The healthcare industry is on a digital transformation journey and EMEA, MEA, Latin America and Asia are fast growing markets with the adoption of precision medicine on an upward trajectory,” said Paul Edwards, CEO of DoseMe. “I am confident that Sigi has the knowledge, skills, proven experience and passion to drive our vision forward and continue to make DoseMe the preferred choice for healthcare organizations.”
In the past year, the company has expanded its distribution network with exclusive resellers across 29 countries. DoseMe continues to focus on product innovation and go-to-market expansion to build new drug models to broaden the MTDM platform. Under Braeuer’s leadership, diversifying the channels and adding new partners will enable the company to offer a wide range of AI-powered systems for real-time patient care.
“DoseMe is at an inflection point as the advent of AI in precision dosing takes shape and is driving the increasing demand around the globe. I am excited to work with these exceptionally talented individuals to achieve our next phase of growth,” said Braeuer.
Peter Sargent new CEO isn’t getting a salary increase from COO
Jim Millen taking a considerable decrease
Who’s betting there is suddenly a contract RNS pretty soon…
And DR S is high fiving himself followed by a options RNS haaaaaa
The directorship stated in RNS are facts.
There is legal responsibilities behind this. This needs to be registered with Companies house and can be done pretty much instantly when you log in??????
I mean a company presentation for a board change does seem weird / OTT
It states Peter has been named director in RNS with immediate effect.
Hasn’t changed on companies house….
I was taking the P@&£
You not know about code 64?
For now....
Why i wonder lol - been there seen that
Let’s see if PYC Twitter team or whatever it’s called jumps all over that tweet….
“Scratches chin”